B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering...
B&K Corporation
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...
Protein Drug Developer B&K Co., Ltd from Qingdao Eyes Hong Kong IPO
B&K Co., Ltd, known as Bio-Bank Corp., a biopharmaceutical company specializing in protein drug development...
Bio-Bank Corp. Aims for HKEX IPO with Focus on PDGF Drug Development
B&K Corporation Limited, known as Bio-Bank Corp., has recently filed an initial public offering (IPO)...